Active, not recruitingPhase 3NCT03897127

Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Ulm
Intervention
Cytarabine(drug)
Enrollment
882 enrolled
Eligibility
18 years · All sexes
Timeline
2019 – 2027

Study locations (30)

Collaborators

Jazz Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03897127 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease →

← Back to all trials